论文部分内容阅读
本文将12倒尿毒症常规血透继发性甲旁亢（SHPT）患者分两组，Ⅰ组（7例）予以透析后静脉注射1，25（OH）2D32μg/次，每周2次；Ⅱ组（5例）予以透析后口服1，25（OH）2D32μg/次，每周2次。治疗前及治疗后2、4、8、12周测血钙、磷、碱性磷酸酶、血清甲状旁腺素；治疗前及治疗后4、12周末做甲状旁腺B超；治疗前、后做双手X线片、测肝肾功能，记录治疗前后临床症状的改变。结果显示，两组血清甲状旁腺素治疗后均明显下降，甲状旁腺缩小，临床症状改善，口服组易出现高钙血症。说明静脉注射1，25（OH）2D3治疗SHPT优于口服。
In this study, 12 patients with conventional hemodialysis secondary hyperparathyroidism (SHPT) were divided into two groups. Group I (n = 7) received intravenous 1,25 (OH) 2D32μg / time, twice a week Group (5 cases) were dialyzed 1,25 (OH) 2D32μg / times, twice a week. Blood calcium, phosphorus, alkaline phosphatase, serum parathyroid hormone were measured before treatment and at 2, 4, 8 and 12 weeks after treatment. Before and after 4 and 12 weeks of treatment, parathyroid B ultrasound was performed. Before and after treatment X-ray film to do both hands, test liver and kidney function, record changes in clinical symptoms before and after treatment. The results showed that serum parathyroid hormone after treatment were significantly decreased in both groups, the parathyroid glands narrowed, clinical symptoms improved, prone to oral hypercalcemia. Intravenous injection of 1,25 (OH) 2D3 SHPT superior to oral.